Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 7Withdrawn 1Unknown 1Terminated 1Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Carcinoma, Non-Small-Cell Lung 70Breast Neoplasms 52Ovarian Neoplasms 43Lung Neoplasms 24Neoplasms 21Neoplasm Metastasis 20Fallopian Tube Neoplasms 20Carcinoma, Ovarian Epithelial 18Triple Negative Breast Neoplasms 10Squamous Cell Carcinoma of Head and Neck 10Uterine Cervical Neoplasms 9Head and Neck Neoplasms 9Stomach Neoplasms 8Recurrence 8Endometrial Neoplasms 8Adenocarcinoma of Lung 8Melanoma 7Esophageal Neoplasms 6Urinary Bladder Neoplasms 5Pancreatic Neoplasms 5Uterine Neoplasms 4Solid Tumors 4Small Cell Lung Carcinoma 4Prostatic Neoplasms 4Adenocarcinoma, Bronchiolo-Alveolar 4Adenocarcinoma Of Esophagus 4Thoracic Neoplasms 3Testicular Neoplasms 3Solid Tumor 3Sarcoma 3

Interventions

Carboplatin 2Capecitabine 2antineoplaston AS 2-1 1antineoplaston A10 1Topotecan 1Paclitaxel 1Mebendazole 1Gemcitabine 1Cyclophosphamide 1Cryosurgery 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Neoplasms, Unknown Primary × Paclitaxel × Clear all
NCT00201734 2016-09-23

Capecitabine, Carboplatin and Weekly Paclitaxel for Patients With Solid Tumors and Adenocarcinoma of Unknown Primary

Ohio State University Comprehensive Cancer Center

Phase 1/2 Terminated
57 enrolled 11 charts
Tumor-Agnostic

Adenocarcinoma, Neoplasms, Neoplasms, Unknown Primary

Data powered by HemOnc (CC BY 4.0) Colophon âš¡